and eTMF systems

For example, a site may receive a digital questionnaire that auto-fills their previous trial performance (e.g., 45 patients enrolled in a diabetes trial in 2022) and requests justification for a proposed higher recruitment rate in the current protocol. Such dynamic functionality reduces overestimation and improves data integrity.

Examples of Widely Used Digital Tools

Several platforms are now widely adopted in feasibility planning and site selection:

• Veeva Vault Study Startup: Offers feasibility tracking, site questionnaires, and document workflow
• Clario Site Feasibility: Provides centralized dashboards, automation, and metrics analytics
• TrialHub: Combines feasibility intelligence and real-world evidence data
• SiteIQ: Scores site responses using historical trial data benchmarks

These tools help eliminate manual communication, standardize site evaluation globally, and shorten trial start-up timelines by 30–50% in some cases. They also allow for early detection of red flags using built-in analytics.

Benefits of Digital Feasibility Collection

Using digital platforms brings significant advantages for sponsors, CROs, and sites:

• Speed: Centralized access accelerates survey completion and review
• Data Quality: Built-in validation ensures clean, usable responses
• Standardization: Uniform questionnaires across global regions
• Audit Readiness: Digital timestamps, versioning, and metadata tracking
• Remote Access: Enables decentralized feasibility from any location
• Integrated Analytics: Feasibility dashboards for real-time decision-making

For example, in a Phase III vaccine trial with 60 sites across Asia and Latin America, using a digital feasibility system reduced the questionnaire review cycle from 15 days to 5, and allowed site prioritization based on algorithmic scoring of patient pool, investigator experience, and previous performance.

Data Privacy and Regulatory Considerations

While digital tools enhance feasibility collection, sponsors must ensure GxP and data privacy compliance. Digital systems must meet:

• 21 CFR Part 11 electronic records/signature compliance (FDA)
• Annex 11 of EU GMP Guidelines (EMA)
• Data encryption and role-based access control
• GDPR for EU-based investigator and patient data

Audit trails are critical. Regulators expect systems to maintain metadata for each action, such as questionnaire issuance, completion, edits, and sign-offs. Failing to maintain a compliant system can lead to inspection findings. A strong vendor selection and validation process is necessary before deployment.

Workflow Example: End-to-End Feasibility Using Digital Platforms

A typical digital feasibility workflow includes:

1. Study team designs a therapeutic-area specific questionnaire on the platform
2. System pulls pre-existing site info (e.g., past enrollment metrics) from CTMS
3. Questionnaire distributed to selected sites with time-bound completion request
4. Sites respond, upload documentation, and e-sign digitally
5. Feasibility manager reviews auto-flagged responses (e.g., low patient pool, delayed start-up)
6. Data exported to dashboards and linked to selection scorecards
7. Selected sites proceed to contract negotiation and SIV scheduling

This automation replaces dozens of email threads, Excel sheets, and redundant document requests. It also ensures inspection-readiness at every step.

Integration with Other Clinical Systems

Digital feasibility tools do not operate in isolation. Leading platforms integrate with:

• Clinical Trial Management Systems (CTMS): Pull historical performance data
• Electronic Trial Master File (eTMF): Archive signed questionnaires and CVs
• eConsent and eCOA platforms: Evaluate site readiness for digital subject interfaces
• Analytics tools: Power BI, Tableau for site scoring dashboards

For instance, when a feasibility questionnaire flags a site’s lack of eConsent capability, that insight can be sent directly to the digital operations team to arrange supplemental training or support.

Challenges in Digital Adoption

Despite benefits, digital feasibility faces challenges:

• Site Resistance: Some smaller or academic sites may lack technical infrastructure
• Platform Training: Investigators and coordinators may need onboarding to navigate tools
• Vendor Oversight: CROs must ensure system validation and GxP compliance
• Localization: Multi-language support and regional question adaptations are often limited

To overcome these, sponsors should involve site staff in platform evaluation, provide helpdesk support, and conduct platform-specific SOP training during feasibility rollout.

Use Case: Oncology Trial Leveraging Digital Feasibility

In a recent multicenter Phase II oncology trial across Europe, a sponsor used a digital feasibility platform with built-in analytics. The tool analyzed previous enrollment history, site IRB timelines, and availability of certified imaging centers. Sites scoring below the threshold were excluded automatically. Results:

• Startup timeline reduced by 22%
• Protocol deviations dropped by 15%
• Enrollment met 100% target within projected window

The sponsor used integration with CTRI India and other global registries to cross-check recruitment histories—further validating questionnaire responses using historical performance data.

Conclusion

Digital platforms are no longer optional in modern clinical trial feasibility planning—they are critical. From automated data validation to centralized analytics and regulatory audit trails, these systems enable smarter, faster, and more compliant trial startup. Sponsors and CROs that adopt digital feasibility tools can reduce risk, cut costs, and improve site selection precision. As trials become increasingly global and decentralized, leveraging digital platforms is the cornerstone of operational excellence in clinical development.